ScholarDeck

Cohort studyEye (London, England) · 2026

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies.

Amelia Rees, Raheej Khan, Jessy Choi … Jane Ashworth

OphthalmologyCohort study

Weekly adalimumab controlled refractory paediatric uveitis in two-thirds of patients.

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies.

Amelia Rees … Jane Ashworth

Eye (London, England) · 2026

Background

Adalimumab (adalimumab) is a well-established treatment for refractory paediatric uveitis; however, some patients remain inadequately controlled on standard biweekly dosing.

Purpose

This study evaluates outcomes of escalation to weekly adalimumab in children with refractory uveitis and explores the relevance of serum drug levels and anti-adalimumab antibodies (anti-ADA antibodies).

Methods

With idiopathic uveitis at two tertiary centres in the UK treated with weekly adalimumab were retrospectively reviewed.

n = 15 patients

Results

adalimumab controlled eye inflammation in two-thirds of children

Pre-escalation

47%

Post-escalation

13.3%

More results

Mean age at escalation was 11 years (range: 3-17).

11 (73%) had a systemic diagnosis; most commonly juvenile idiopathic arthritis (60%).

Median serum level pre-escalation was 10.1 mg/L (IQR: 7.8-11.9) and 18.1 mg/L (IQR: 14.8-22.1) post escalation.

More results

AAAs were detectable in 7/15 (47%) pre-escalation, 2/15 (13.3%) post-escalation.

“

Conclusion · 1 of 2

Weekly adalimumab offers a safe and effective treatment alternative for children with refractory uveitis, including those with AAAs.

Conclusion · 2 of 2

These findings support its inclusion in future treatment pathways, though the predictive value of serum levels and AAAs remains uncertain and warrants further investigation.

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies.

Related papers